Dihexa peptide is currently not widely available as it is still under investigation and pending approval through clinical trials
Berkovic MC, Virovic-Jukic L, Bilic-Curcic I, Mrzljak A
It has shown significant promise as an effective intervention against type 2 diabetes (T2D) and excessive body weight, resulting in the United States Food and Drug Administration (FDA) approving its use against both conditions in May 2022 for T2D and November 2023 for obesity
It does not trigger the rise in cortisol levels that could negatively affect muscle cell health and bone density in aging subjects
The human gut microbiome displays diurnal and seasonal rhythmic patterns, abstract 395, on Sunday, May 7, at 11:20 am, Digestive Disease Week (2023) in Chicago, IL Yildiz, S., et al